

## **High-throughput In silico drug screen against Mpox targeted proteins in comparison with repurposed antiviral drugs against Natural compounds**

### **Abstract**

The recent resurgence of the Monkeypox Virus (MPXV) has prompted increased efforts to discover effective antiviral treatments. This study utilized an in silico docking approach with CB Dock2 to assess both natural compounds and repurposed antiviral medications. We concentrated on several critical viral targets for inhibition, specifically VP39 2'-O Methyltransferase, viral topoisomerase-DNA complexes, and poxin. Our results identified a number of natural substances, including Physalin A, Sitoindoside IX, Withanolide, Shatavarin 1, Kutkoside, and Berberine HCl, as promising inhibitors. Tecovirimat was found to be the most effective among the repurposed antivirals. Notably, natural products like Withanolide, Sitoindoside IX, and Physalin A showed significant inhibitory potential based on their Vina scores and binding affinities, suggesting they may serve as alternative therapeutic options. Tecovirimat consistently proved to be the most powerful inhibitor among repurposed antivirals across all examined targets, reinforcing its importance in combating MPXV.

**Keywords:** Monkeypox Virus (MPXV), VP39 2'-O Methyltransferase, viral topoisomerase-DNA complexes, and poxin, Physalin A, Sitoindoside IX, Withanolide, Shatavarin 1, Kutkoside and Berberine Hydrochloride, Tecovirimat, In Silico High-Throughput, Drug targets, Protein Data Bank ID-8B07, Protein Data Bank ID-3IGC, Protein Data Bank ID-8C9K

### **Introduction**

Monkeypox virus (MPXV), a zoonotic Orthopoxvirus, has recently become a global health concern due to its spread beyond its traditional endemic regions in Central and West Africa. First identified in humans in 1970, MPXV has historically been limited to these regions, where it is transmitted primarily through animal reservoirs. However, recent outbreaks in Europe, North America, and other parts of the world have heightened global alarm. In response, the World Health Organization (WHO) declared monkeypox a Public Health Emergency of International Concern (PHEIC) in July 2022 [1]. MPXV poses a serious health threat, particularly because it has a higher fatality rate than smallpox and can cause severe symptoms, including painful skin lesions, respiratory distress, and systemic complications [2].

Currently, the availability of approved antiviral treatments for MPXV is limited, which underscores the urgent need for new therapeutic approaches. While vaccines, such as the smallpox vaccine, offer some protection against MPXV, they are not widely accessible, and the zoonotic nature of the virus complicates eradication efforts. MPXV can infect a wide range of animal species, making containment challenging and increasing the potential for recurrent outbreaks [3] [4]. Studies suggest that MPXV may adapt to different hosts over time, further complicating the development of effective control measures [5].

Public health agencies, including the Centers for Disease Control and Prevention (CDC) and WHO, have emphasized the need for intensified research efforts to discover new antiviral

therapies, particularly for vulnerable populations such as immunocompromised individuals. The similarities between MPXV and the variola virus, which causes smallpox, make it a critical target for antiviral drug development [6]. Targeting viral proteins essential for replication, genome maintenance, and immune evasion could yield promising therapeutic strategies.

Recent studies have identified three key proteins in MPXV that serve as potential drug targets: VP39 2'-O Methyltransferase, viral topoisomerase, and Poxin. Each of these proteins plays a distinct and essential role in the virus's life cycle. VP39 2'-O Methyltransferase is involved in viral RNA capping, a process crucial for stabilizing viral mRNA and ensuring efficient replication. Viral topoisomerase facilitates DNA unwinding during replication, while Poxin aids in immune evasion by degrading host defence molecules [7] [8]. Inhibiting these proteins could disrupt the virus's ability to replicate and spread, offering a promising avenue for new antiviral drug development. By targeting these critical proteins, researchers hope to develop therapies that will not only manage current outbreaks.

### **1. VP39 2'-O Methyltransferase (PDBID-8B07)**

#### **Role in Mpox Pathogenesis**

VP39 is a critical component in viral mRNA processing [9]. This enzyme carries out 2'-O methylation of the 5' cap of viral mRNA, a modification necessary for the proper recognition of viral mRNAs by the host cell's translation machinery [10]. Without this modification, the host's immune system can more easily recognize and degrade the viral RNA, significantly impairing the virus's ability to replicate.

In addition to enhancing translation efficiency, VP39-mediated methylation protects viral RNA from being detected by host antiviral defences, such as the interferon response [11]. This dual role in ensuring efficient translation and immune evasion makes VP39 an attractive drug target. Inhibiting VP39 can reduce viral protein synthesis and expose the virus to the host's innate immune system [11].

#### **Drug Target Potential**

Inhibitors of VP39 methyltransferase activity would prevent the virus from effectively replicating within host cells [10,11]. By obstructing this enzyme, the virus's ability to mask its RNA from the immune system is diminished, potentially leading to rapid viral clearance by the host [11].

### **2. Viral Topoisomerase-DNA Complex (PDBID-3IGC)**

#### **Role in Mpox Pathogenesis**

The viral topoisomerase is a crucial enzyme that resolves topological issues arising during DNA replication and transcription [12]. In the case of the Mpox virus, which possesses a large and complex DNA genome, topoisomerase ensures that the viral DNA can be unwound and rewound appropriately [13]. The Mpox topoisomerase interacts with the viral genome, introducing temporary breaks to relieve torsional stress during replication [14]. If the enzyme's activity is disrupted, the replication fork may stall, resulting in incomplete viral DNA replication [14].

Given the need for efficient replication of the viral genome, the viral topoisomerase is integral to the successful production of progeny viruses. This enzyme also plays a role in reducing supercoiling and ensuring that transcription proceeds smoothly, further emphasizing its importance in pathogenesis.

### **Drug Target Potential**

Targeting the viral topoisomerase can disrupt MPXV's ability to replicate its genome, thereby reducing viral propagation [14]. Drugs designed to stabilize the topoisomerase-DNA complex or inhibit its function could lead to irreversible DNA damage in the virus, halting its life cycle.

## **3. Poxin (PDBID-8C9K)**

### **Role in Mpox Pathogenesis**

Poxin proteins are key mediators in viral immune evasion [15]. MPXV uses Poxins to degrade host immune signalling molecules like cyclic GMP-AMP (cGAMP) [16], a critical molecule in the STING (Stimulator of Interferon Genes) pathway [16]. This pathway is essential for initiating an antiviral state in host cells. By degrading cGAMP, Poxins prevent the activation of the STING pathway, allowing the virus to evade detection and avoid triggering the host's antiviral responses, such as the production of interferons and inflammatory cytokines [17].

This ability to suppress the innate immune response is vital for the virus to establish infection and spread within the host. Without functional Poxins, the virus would be subject to rapid immune clearance, making Poxin an essential player in MPXV pathogenesis.

### **Drug Target Potential**

Inhibiting Poxin function could restore the host's ability to recognize and mount an immune response against the virus. Blocking Poxin would allow cGAMP to accumulate, leading to STING activation and the subsequent production of interferons that limit viral spread. Developing inhibitors for Poxins could enhance host immunity and reduce viral persistence [18].

The structural and functional roles of VP39 2'-O Methyltransferase, viral topoisomerase, and Poxin in MPXV pathogenesis highlight their importance as drug targets [19]. Inhibiting these proteins could interfere with viral replication, transcription, and immune evasion mechanisms, making them critical focal points for antiviral drug development. Strategies that target these proteins can potentially curtail Mpox virus infections, providing therapeutic options to manage outbreaks [20].

Currently, Tecovirimat (TPOXX) is the only FDA-approved antiviral for treating mpox [21]. It targets the VP37 protein, which is essential for viral particle formation and spread in orthopoxviruses, including mpox [22]. The drug is especially recommended for severe cases, immunocompromised patients, and others with higher risks of complications.

Another drug, Brincidofovir (Tembexa), is an antiviral used experimentally against DNA viruses like smallpox and mpox [23]. However, its use is less frequent due to limited clinical data on mpox-specific efficacy.

Tecovirimat, an FDA-approved antiviral for smallpox, has shown promise against MPXV due to its inhibition of the VP39 2'-O Methyltransferase [24]. However, there is a growing interest in natural products as alternative or complementary antiviral therapies. The exploration of phytochemicals, known for their wide range of bioactive properties, could provide new insights into drug discovery. In this study, we leverage the power of in silico docking using CB Dock2 to evaluate the binding affinities of natural products alongside Tecovirimat.

### **Potential natural antiviral drugs:**

Several natural products have demonstrated promising antiviral properties in various studies, showing their potential as therapeutic agents against viral infections [25]. Physalin A, a bioactive compound isolated from *Physalis* species, has shown significant antiviral activity, particularly against the hepatitis C virus (HCV) and Epstein-Barr virus (EBV), by inhibiting viral replication and modulating immune responses [26]. Sitoindoside IX, a bioactive steroidal lactone found in *Withaniasomnifera* (Ashwagandha), has also been investigated for its antiviral potential, showing inhibitory effects against herpes simplex virus (HSV) through immunomodulatory mechanisms [27].

Withanolide, another compound derived from *Withaniasomnifera*, has been explored for its antiviral activity against multiple viruses, including the influenza virus and HCV [28]. This compound primarily works by disrupting viral entry and replication pathways, making it a candidate for further investigation in antiviral drug development. Shatavarin 1, a saponin glycoside found in *Asparagus racemosus*, has exhibited antiviral properties against respiratory viruses by strengthening the host's immune response and preventing viral multiplication [29].

Kutkoside, an iridoid glycoside isolated from *Picrorhizakurroa*, has shown potent antiviral activity, particularly against the hepatitis B virus (HBV) [30]. Studies suggest that it exerts its effect by inhibiting viral DNA replication. Lastly, Berberine HCl, an alkaloid present in *Berberis* species, has been extensively researched for its antiviral properties [31], with demonstrated efficacy against human immunodeficiency virus (HIV), influenza, and herpes viruses. Berberine inhibits viral replication and modulates inflammatory pathways, making it a versatile antiviral agent with broad-spectrum activity.

### **Global declaration:**

Eurosurveillance recently released articles addressing the ongoing outbreak. In a rapid communication dated 14 March 2024, findings from genomic sequencing of viral genomes were shared to shed light on the strains responsible for the outbreak [32]. The global response to the MPXV outbreak, as emphasized by organizations like the WHO and CDC, calls for a comprehensive strategy that includes not only vaccination but also the development of new antiviral therapies [33]. This study contributes to that narrative by identifying viable candidates for drug development and reinforces the importance of exploring diverse sources for antiviral compounds.

## **Methodology**

### **Protein and Ligand Preparation**

Protein structures of VP39 2'-O Methyltransferase (PDBID-8B07), viral topoisomerase-DNA complex (PDBID-3IGC), and Poxin (PDBID-8C9K) as shown in **figure 3 A, B, C** were

retrieved from the Protein Data Bank. The natural ligands, including Physalin A, Withanolide, Shatavarin 1, and other natural products, were obtained from the PubChem database and prepared in their 3D conformations as shown in **figure 2**. These ligands were energy minimized using the MMFF94 force field, ensuring that the ligands were in their most stable and optimal form for docking.

### **Docking Protocol using CB Dock2**

CB Dock2 is a popular tool for performing docking studies and utilizes the AutoDock Vina algorithm. CB Dock2 operates by automatically identifying binding cavities in the protein structure through a grid-based cavity prediction algorithm. Once these cavities are identified, the ligands are prepared by minimizing their energy to avoid any high-energy conformations that could interfere with the docking process [34].

The software uses a scoring function that evaluates binding affinities based on intermolecular forces, including hydrogen bonds, van der Waals interactions, and hydrophobic contacts. The Vina algorithm iteratively improves the binding pose of the ligand by adjusting the position and orientation of the ligand within the binding site, with the final score representing the free binding energy in kcal/mol.

### **CB Dock2 Algorithm and Workflow**

CB Dock2 employs a unique combination of cavity detection and docking algorithms. First, the cavity detection algorithm analyses the 3D structure of the protein, identifying the most likely binding sites based on geometric features, such as crevices and pockets on the protein surface. The ligand is then docked into these predicted cavities, and the Vina algorithm refines the orientation of the ligand based on the calculated interaction energy [35].

The Vina algorithm uses an optimization technique that minimizes the predicted binding energy by evaluating multiple possible orientations of the ligand within the binding site. The final docking pose represents the orientation with the lowest energy, which is assumed to correspond to the most favourable binding interaction. The algorithm evaluates multiple factors, including hydrogen bonding, hydrophobic effects, and electrostatic interactions, to produce a binding score in kcal/mol [34] [35].

CB-Dock2 improves molecular docking by combining cavity detection and ligand docking into a streamlined process. The methodology involves multiple steps, beginning with cavity detection using a fast Fourier transform (FFT) algorithm to analyse the protein surface [34, 35]. This method identifies potential binding pockets based on the surface's geometric concavities. Cavities are ranked by volume and shape, determining the most likely binding site for ligands.

Once the cavity is identified, Auto Dock Vina performs docking simulations. Vina uses a stochastic global search algorithm to find optimal ligand poses by minimizing the free energy of binding. The algorithm combines various interaction forces, including van der Waals, hydrophobic interactions, hydrogen bonding, and torsional penalties to calculate the binding energy.

**The scoring function is expressed as:**

$$\Delta G_{\text{binding}} = \Delta G_{\text{vdW}} + \Delta G_{\text{hydrophobic}} + \Delta G_{\text{H-bond}} + \Delta G_{\text{torsion}}$$

Where:

- $\Delta G_{\text{vdW}}$  accounts for van der Waals interactions,
- $\Delta G_{\text{hydrophobic}}$  accounts for hydrophobic interactions,
- $\Delta G_{\text{H-bond}}$  represents hydrogen bonding energy, and
- $\Delta G_{\text{torsion}}$  reflects the penalty for ligand torsional flexibility.

CB-Dock2 also integrates genetic algorithms (GA) to handle ligand flexibility [34] [35]. The ligand is sampled in various conformations, and the GA explores the conformational space through iterative mutation, selection, and crossover, optimizing the best ligand poses. The process ranks docking poses based on their predicted binding energies, with the most energetically favourable conformations presented as the final results.

By leveraging cavity detection and the flexibility of docking algorithms, CB-Dock2 enhances both accuracy and efficiency in predicting how ligands bind to protein targets, making it a useful tool in computational drug design [34] [35].

## Results

The docking results revealed that several natural products exhibited promising binding affinities with the selected MPXV targets. Physalin A emerged as a potent inhibitor with a Vina score of -10.3 kcal/mol against VP39 2'-O Methyltransferase, indicating strong hydrogen bonding and hydrophobic interactions. Similarly, Withanolide showed a favourable binding score (-9.1 kcal/mol), making it a potential candidate for MPXV inhibition. These findings are significant as they suggest that natural products could play a vital role in developing alternative antiviral treatments for MPXV.

The docking analysis for MPXV proteins with PDB IDs 8C9K and 8B07 revealed promising results for several natural compounds. Withanolide demonstrated the highest binding affinity, achieving a Vina score of -10.7 kcal/mol, indicating it as a strong potential inhibitor. Sitoindoside IX and Physalin A both followed closely with Vina scores of -10.3 kcal/mol, suggesting they also have significant potential as MPXV inhibitors. Tecovirimat, a known antiviral, displayed a Vina score of -9.6 kcal/mol, which was also matched by Kutkoside, showing that these natural products may perform comparably to existing antiviral treatments. Other compounds, including Shatavarin 1 and Berberine HCl, showed moderate binding affinities with Vina scores of -8.6 kcal/mol and -8.3 kcal/mol, respectively. These findings indicate that natural compounds, particularly Withanolide, Sitoindoside IX, and Physalin A, hold potential for the development of alternative antiviral treatments targeting MPXV.

Tecovirimat, the chemical antiviral, displayed the s binding affinity across all targets, with a Vina score of -10.3 kcal/mol for VP39 2'-O Methyltransferase and -9.9 kcal/mol for the viral topoisomerase-DNA complex. Its ability to inhibit multiple critical viral enzymes makes it a highly effective antiviral agent. However, the growing concerns around antiviral resistance necessitate the search for complementary therapies, particularly from natural sources.

This study provides preliminary evidence supporting the potential of natural compounds like PhysalinA, Sitoindoside IX and Withanolide in inhibiting MPXV. These natural inhibitors

demonstrated comparable binding affinities to Tecovirimat, particularly against viral topoisomerase-DNA complex (PDBID-3IGC), and Poxin (PDBID-8C9K), VP39 2'-O Methyltransferase see **Figure 1 & Table 1**. Further in vitro and in vivo studies are required to validate these findings, but the in-silico results are encouraging.

The involvement of global health organizations such as the WHO and CDC in addressing the current MPXV outbreak highlights the importance of continued research into antiviral agents. The WHO has emphasized the need for a multi-faceted approach that includes not only vaccination but also the development of new antiviral treatments. By exploring natural products and their efficacy, this study contributes to the growing body of research aimed at finding novel solutions for MPXV.

## **Discussion**

The findings from this study underscore the urgent need for effective therapeutic strategies against monkeypox virus (MPXV), particularly in light of its rising incidence and potential for severe health consequences. The comparative analysis of the binding affinities of natural compounds with key viral proteins—VP39 2'-O Methyltransferase, viral topoisomerase, and Poxin—reveals promising candidates for antiviral development.

The selection of VP39, topoisomerase, and Poxin as drug targets is particularly relevant given their distinct roles in MPXV pathogenesis. VP39's function in mRNA cap methylation not only facilitates efficient translation of viral proteins but also aids in immune evasion, making it a critical target. Inhibitors that can disrupt this protein may enhance the host immune response, leading to improved viral clearance. The binding affinity of Physalin A (-10.3 kcal/mol) highlights its potential as a lead compound, suggesting that further exploration into its mechanism could yield effective antiviral therapies.

Similarly, targeting the viral topoisomerase is crucial due to its involvement in DNA replication and transcription. The ability of natural products, particularly Withanolide and Sitoindoside IX, to achieve high binding affinities (-10.7 and -10.3 kcal/mol respectively) suggests they could serve as templates for developing new inhibitors that disrupt MPXV replication. These findings are promising, especially given the historical challenges of creating effective antivirals for DNA viruses.

Poxin's role in immune suppression presents another therapeutic opportunity. By degrading cGAMP, Poxin prevents the activation of the STING pathway, which is vital for initiating antiviral immune responses. Inhibitors of Poxin could potentially restore the host's immune vigilance, making it a strategic target for drug development.

The exploration of natural products as antiviral agents represents an innovative approach to addressing the limitations of current therapies like Tecovirimat and Brincidofovir. The binding affinities exhibited by the natural compounds in this study indicate that they may not only complement existing treatments but could also help mitigate the risk of antiviral resistance—a significant concern as the MPXV outbreak continues.

The results showing comparable binding affinities between natural compounds and established antivirals signal the potential for these natural products to be integrated into therapeutic regimens. For instance, Withanolide's potent binding suggests it could enhance

therapeutic efficacy, particularly for high-risk populations, including immunocompromised individuals who are disproportionately affected by MPXV.

The preliminary *in silico* findings necessitate further validation through *in vitro* and *in vivo* studies to establish the clinical relevance of these natural compounds. Investigating their pharmacokinetics, safety profiles, and mechanisms of action will be crucial steps in their development as therapeutic agents. Additionally, the synergistic potential of combining these natural products with existing antiviral drugs should be explored to enhance treatment efficacy and broaden the therapeutic arsenal against MPXV.

The results of this study indicate that targeting VP39 2'-O Methyltransferase, viral topoisomerase, and Poxin with natural products holds promise for the development of effective antiviral therapies against MPXV. Given the ongoing threat posed by this emerging infectious disease, continued research and innovation in this area are imperative for public health.

## **Conclusion**

This study highlights the promising potential of targeting key viral proteins—VP39 2'-O Methyltransferase, viral topoisomerase, and Poxin—as effective strategies for developing novel antiviral therapies against the Monkeypox Virus (MPXV). The compelling binding affinities observed with natural compounds such as Physalin A, Withanolide, and Sitoundoside IX offer hope for these agents as viable therapeutic candidates. These compounds could play a pivotal role in either enhancing or complementing existing treatments, such as Tecovirimat, which has shown efficacy in MPXV management. The ability of these natural products to disrupt essential viral functions represents not only a significant scientific breakthrough but also introduces an innovative approach to addressing the virus. This becomes especially relevant as we face the rising challenge of resistance to conventional antivirals.

The significance of these findings lies in their potential to expand the current arsenal of antiviral therapies. In a world where viral outbreaks continue to pose serious public health threats, relying solely on a limited number of treatments is insufficient. Natural products, with their diverse chemical structures and biological properties, present an untapped reservoir of antiviral potential. By targeting multiple viral proteins, these compounds may offer a multi-faceted approach to combating MPXV, thereby reducing the likelihood of resistance and ensuring more comprehensive viral inhibition.


Furthermore, the urgency of the global health crisis posed by the ongoing MPXV outbreaks cannot be overstated. With cases increasing worldwide, the need for new, effective therapies is critical. While Tecovirimat remains a strong contender, this study suggests that natural compounds could either work synergistically with existing treatments or serve as alternatives in cases where traditional antivirals fail. Therefore, further research into these compounds, including *in vitro* and *in vivo* studies, is not only recommended but necessary. Such studies will help clarify their mechanisms of action, optimize their efficacy, and ensure their safety in clinical settings.

Ultimately, this work contributes significantly to our understanding of MPXV pathogenesis and emphasizes the value of exploring diverse and unconventional sources for antiviral agents. By prioritizing the development of natural products as potential therapies, we align

with broader global health efforts to manage and mitigate the spread of emerging infectious diseases. This approach not only enhances our preparedness but also strengthens our ability to respond effectively to future outbreaks, thereby protecting public health and ensuring long-term resilience in the face of viral threats. The exploration of these natural compounds opens the door to new possibilities, bridging the gap between traditional medicine and modern antiviral strategies, and offering hope for a future where MPXV and other emerging diseases can be more effectively controlled.

**Table 1: Docking results of the natural products and Tecovirimat against the monkeypox virus targets based on the data provided:**



<b>Product</b>	<b>VP39 2'-O Methyltransferase (PDBID-8B07)-Vina scores c</b>	<b>Viral Topoisomerase-DNA Complex (PDBID-3IGC) Vina score c</b>	<b>Poxin (PDBID-8C9K) Vina score c</b>
<b>Withanolide</b>	-10.7	-10.7	11.3
<b>Sitoindoside IX</b>	-10.3	-10.3	9.6
<b>Shatavarin 1</b>	-8.6	9.3	8.4
<b>Physalin A</b>	-10.3	-10.6	9.6
<b>Kutkoside</b>	-9.6	8.2	7.8
<b>Berberine HCl</b>	-8.3	8.4	7.3
<b>Chlorogenic Acid</b>	7.3	7.8	7.9
<b>Tecovirimat</b>	-10.3	-9.9	9.1



**Figure1:** In Silico High-Throughput Screening of Poxin, VP39 2'-O Methyltransferase, and Viral Topoisomerase-DNA Complexes as Drug Targets for Monkeypox Virus and their potential Inhibitors [9] [16] [36]

UNDER PEER REVIEW

**Figure 2:** 1. Shatavarin 1 [37], 2. Sitoindoside IX [38], 3. Physalin A [39], 4. Withanolide [40], 5. Berberine [41] 6. Kutkoside [42], 7. Chlorogenic acid [43], 8. Tecovirimat [44]



**Figure 3:** A : Viral Topoisomerase, B:VP39 2'-O Methyltransferase. C:Poxin[9] [16] [36]

## References

1. Nuzzo, J. B., Borio, L. L., & Gostin, L. O. (2022). The WHO declaration of monkeypox as a global public health emergency. *Jama*, 328(7), 615-617.
2. McCollum, A. M., & Damon, I. K. (2014). Human monkeypox. *Clinical infectious diseases*, 58(2), 260-267
3. Alzhanova, D., Edwards, D. M., Hammarlund, E., Scholz, I. G., Horst, D., Wagner, M. J., ... & Früh, K. (2009). Cowpox virus inhibits the transporter associated with antigen processing to evade T cell recognition. *Cell host & microbe*, 6(5), 433-445.
4. Hakim, M. S., & Widyaningsih, S. A. (2023). The recent re-emergence of human monkeypox: Would it become endemic beyond Africa. *Journal of Infection and Public Health*, 16(3), 332-340.
5. Reynolds, M. G., Carroll, D. S., & Karem, K. L. (2012). Factors affecting the likelihood of monkeypox's emergence and spread in the post-smallpox era. *Current Opinion in Virology*, 2(3), 335-343.
6. Moss, B. (2013). Poxvirus DNA replication. *Cold Spring Harbor perspectives in biology*, 5(9), a010199
7. Shuman, S. (1991). Recombination mediated by vaccinia virus DNA topoisomerase I in *Escherichia coli* is sequence specific. *Proceedings of the National Academy of Sciences*, 88(22), 10104-10108.
8. De Vivo, M., & Cavalli, A. (2017). Recent advances in dynamic docking for drug discovery. *Wiley Interdisciplinary Reviews: Computational Molecular Science*, 7(6), e1320.
9. Silhan, J., Klima, M., Otava, T. et al. Discovery and structural characterization of monkeypox virus methyltransferase VP39 inhibitors reveal similarities to SARS-CoV-2 nsp14 methyltransferase. *Nat Commun* 14, 2259 (2023). <https://doi.org/10.1038/s41467-023-38019-1>
10. Zgarbova, Michala & Otava, Tomas & Silhan, Jan & Nencka, Radim & Weber, Jan & Boura, Evzen. (2023). Inhibitors of mpox VP39 2'-O methyltransferase efficiently inhibit the monkeypox virus. *Antiviral Research*. 218. 105714. 10.1016/j.antiviral.2023.105714.
11. Yuta Tsukamoto, Manabu Igarashi, Hiroki Kato, Targeting cap1 RNA methyltransferases as an antiviral strategy, *Cell Chemical Biology*, Volume 31, Issue 1, 2024, Pages 86-99, <https://doi.org/10.1016/j.chembiol.2023.11.011>.
12. Perry K, Hwang Y, Bushman FD, Van Duyn GD. Insights from the structure of a smallpox virus topoisomerase-DNA transition state mimic. *Structure*. 2010 Jan 13;18(1):127-37. doi: 10.1016/j.str.2009.10.020. PMID: 20152159; PMCID: PMC2822398.
13. Sagdat K, Batyrkhan A, Kanayeva D. Exploring monkeypox virus proteins and rapid detection techniques. *Front Cell Infect Microbiol*. 2024 May 28;14:1414224. doi: 10.3389/fcimb.2024.1414224. PMID: 38863833; PMCID: PMC11165096.
14. Hu X, An S, Chu J, Liang B, Liao Y, Jiang J, Lin Y, Ye L, Liang H. Potential Inhibitors of Monkeypox Virus Revealed by Molecular Modeling Approach to Viral DNA Topoisomerase I. *Molecules*. 2023 Feb 2;28(3):1444. doi: 10.3390/molecules28031444. PMID: 36771105; PMCID: PMC9919579.
15. Chaturanga K, Weerawardhana A, Dodantenna N, Lee JS. Regulation of antiviral innate immune signaling and viral evasion following viral genome sensing. *Exp Mol*

- Med. 2021 Nov;53(11):1647-1668. doi: 10.1038/s12276-021-00691-y. Epub 2021 Nov 16. PMID: 34782737; PMCID: PMC8592830.
16. Duchoslav V, Boura E. Structure of monkeypox virus poxin: implications for drug design. *Arch Virol.* 2023 Jun 28;168(7):192. doi: 10.1007/s00705-023-05824-4. PMID: 37378908; PMCID: PMC10307694.
  17. Xue-Mei Yi, Ya-Li Lei, Mi Li, Li Zhong, Shu Li, The monkeypox virus-host interplays, *Cell Insight*, Volume 3, Issue 5, 2024, 100185, ISSN 2772-8927, <https://doi.org/10.1016/j.cellin.2024.100185>.
  18. Bruno Hernández et al. Viral cGAMP nuclease reveals the essential role of DNA sensing in protection against acute lethal virus infection. *Sci. Adv.* 6, eabb4565(2020). DOI:10.1126/sciadv.abb4565
  19. Bachar, S. C., Mazumder, K., Bachar, R., Aktar, A., & Al Mahtab, M. (2021). A review of medicinal plants with antiviral activity available in Bangladesh and mechanistic insight into their bioactive metabolites on SARS-CoV-2, HIV and HBV. *Frontiers in Pharmacology*, 12, 732891.
  20. Byrareddy SN, Sharma K, Sachdev S, Reddy AS, Acharya A, Klaustermeier KM, Lorson CL, Singh K. Potential therapeutic targets for Mpox: the evidence to date. *Expert Opin Ther Targets.* 2023 Jan-Jun;27(6):419-431. doi: 10.1080/14728222.2023.2230361. Epub 2023 Jul 4. PMID: 37368464; PMCID: PMC10722886.
  21. O'Laughlin K, Tobolowsky FA, Elmor R, Overton R, O'Connor SM, Damon IK, Petersen BW, Rao AK, Chatham-Stephens K, Yu P, Yu Y; CDC Monkeypox Tecovirimat Data Abstraction Team. Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022. *MMWR Morb Mortal Wkly Rep.* 2022 Sep 16;71(37):1190-1195. doi: 10.15585/mmwr.mm7137e1. PMID: 36107794; PMCID: PMC9484807.
  22. Russo AT, Grosenbach DW, Chinsangaram J, Honeychurch KM, Long PG, Lovejoy C, Maiti B, Meara I, Hruby DE. An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. *Expert Rev Anti Infect Ther.* 2021 Mar;19(3):331-344. doi: 10.1080/14787210.2020.1819791. Epub 2020 Sep 15. PMID: 32882158; PMCID: PMC9491074.
  23. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Brincidofovir. [Updated 2022 Oct 18]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK585270/>
  24. DeLaurentis CE, Kiser J, Zucker J. New Perspectives on Antimicrobial Agents: Tecovirimat for Treatment of Human Monkeypox Virus. *Antimicrob Agents Chemother.* 2022 Dec 20;66(12):e0122622. doi: 10.1128/aac.01226-22. Epub 2022 Nov 14. PMID: 36374026; PMCID: PMC9765296.
  25. Ribeiro-Filho J, Teles YCF, Igoli JO, Capasso R. Editorial: New trends in natural product research for inflammatory and infectious diseases. *Front Pharmacol.* 2022 Aug 15;13:975079. doi: 10.3389/fphar.2022.975079. PMID: 36046835; PMCID: PMC9421362.
  26. Akram, Muhammad & Mandal, Anirban & Mukherjee, Arindam & Bandyopadhyay, Ritika & Rangasamy, Surendar & Zainab, Rida & Khalil, Muhammad & Parmar,

- Pragnesh & Laila, Umme. (2024). Inhibitory Potential of Medicinal Plants Against Viral Pathogens and their Putative Modes of Action. *Hosts and Viruses*. 10.10.17582/journal.hv/2023/10.58.71.
27. Ozeer, F.Z., Nagandran, S., Wu, Y.S. *et al.* A comprehensive review of phytochemicals of *Withaniasomnifera* (L.) Dunal (Solanaceae) as antiviral therapeutics. *Discov Appl Sci* **6**, 187 (2024). <https://doi.org/10.1007/s42452-024-05845-x>
  28. Jayaprakasam, B., Zhang, Y., Seeram, N. P., & Nair, M. G. (2003). Growth inhibition of human tumor cell lines by withanolides from *Withaniasomnifera* leaves. *Life sciences*, 74(1), 125-132.
  29. Chikhale RV, Sinha SK, Patil RB, Prasad SK, Shakya A, Gurav N, Prasad R, Dhaswadikar SR, Wanjari M, Gurav SS. In-silico investigation of phytochemicals from *Asparagus racemosus* as plausible antiviral agent in COVID-19. *J Biomol Struct Dyn*. 2021 Sep;39(14):5033-5047. doi: 10.1080/07391102.2020.1784289. Epub 2020 Jun 24. PMID: 32579064; PMCID: PMC7335809.
  30. Bhattacharjee, Siddhendu & Bhattacharya, Sibasis & Jana, Sampriti. (2013). A REVIEW ON MEDICINALLY IMPORTANT SPECIES OF PICRORHIZA A REVIEW ON MEDICINALLY IMPORTANT SPECIES OF PICRORHIZA. 2. 1-16.
  31. Warowicka A, Nawrot R, Gozdicka-Jozefiak A. Antiviral activity of berberine. *Arch Virol*. 2020 Sep;165(9):1935-1945. doi: 10.1007/s00705-020-04706-3. Epub 2020 Jun 28. PMID: 32594322; PMCID: PMC7320912.
  32. Eurosurveillance editorial team. Note from the editors: WHO declares mpox outbreak a public health emergency of international concern. *Euro Surveill*. 2024;29(33): pii=240815v. <https://doi.org/10.2807/1560-7917.ES.2024.29.33.240815v>
  33. Masirika Leandre Murhula, Udahemuka Jean Claude, Schuele Leonard, NdishimyePacifique, Otani Saria, Mbiribindi Justin Bengehya, Marekani Jean M., Mambo Léandre Mutimbwa, Bubala Nadine Malyamungu, Boter Marjan, Nieuwenhuijse David F., Lang Trudie, Kalalizi Ernest Balyahamwabo, Musabyimana Jean Pierre, Aarestrup Frank M., Koopmans Marion, Oude Munnink Bas B., Siangoli Freddy Belesi. Ongoing mpox outbreak in Kamituga, South Kivu province, associated with monkeypox virus of a novel Clade I sub-lineage, Democratic Republic of the Congo, 2024. *Euro Surveill*. 2024;29(11):pii=2400106. <https://doi.org/10.2807/1560-7917.ES.2024.29.11.2400106>
  34. Yang Liu, Xiaocong Yang, Jianhong Gan, Shuang Chen, Zhi-Xiong Xiao, Yang Cao, CB-Dock2: improved protein–ligand blind docking by integrating cavity detection, docking and homologous template fitting, *Nucleic Acids Research*, Volume 50, Issue W1, 5 July 2022, Pages W159–W164, <https://doi.org/10.1093/nar/gkac394>
  35. Xiaocong Yang, Yang Liu, Jianhong Gan, Zhi-Xiong Xiao, Yang Cao, FitDock: protein–ligand docking by template fitting, *Briefings in Bioinformatics*, Volume 23, Issue 3, May 2022, bbac087, <https://doi.org/10.1093/bib/bbac087>
  36. Madej T, Lanczycki CJ, Zhang D, Thiessen PA, Geer RC, Marchler-Bauer A, Bryant SH. " MMDB and VAST+: tracking structural similarities between macromolecular complexes. *Nucleic Acids Res*. 2014 Jan; 42(Database issue):D297-303

37. National Center for Biotechnology Information. "PubChem Compound Summary for CID 101406647, Shatavarin I" PubChem, <https://pubchem.ncbi.nlm.nih.gov/compound/Shatavarin-I>. Accessed 2 October, 2024.
38. National Center for Biotechnology Information. "PubChem Compound Summary for CID 189586, Sitoindoside IX" PubChem, <https://pubchem.ncbi.nlm.nih.gov/compound/Sitoindoside-IX>. Accessed 2 October, 2024.
39. National Center for Biotechnology Information. "PubChem Compound Summary for CID 44577487, Physalin A" PubChem, <https://pubchem.ncbi.nlm.nih.gov/compound/Physalin-A>. Accessed 2 October, 2024.
40. National Center for Biotechnology Information. "PubChem Compound Summary for CID 53477765, Withanolide" PubChem, <https://pubchem.ncbi.nlm.nih.gov/compound/Withanolide>. Accessed 2 October, 2024.
41. National Center for Biotechnology Information. "PubChem Compound Summary for CID 2353, Berberine" PubChem, <https://pubchem.ncbi.nlm.nih.gov/compound/Berberine>. Accessed 2 October, 2024.
42. National Center for Biotechnology Information. "PubChem Compound Summary for CID 182265, Kutkoside" PubChem, <https://pubchem.ncbi.nlm.nih.gov/compound/Kutkoside>. Accessed 2 October, 2024.
43. National Center for Biotechnology Information. "PubChem Compound Summary for CID 1794427, Chlorogenic Acid" PubChem, <https://pubchem.ncbi.nlm.nih.gov/compound/Chlorogenic-Acid>. Accessed 2 October, 2024.
44. National Center for Biotechnology Information. "PubChem Compound Summary for CID 16124688, Tecovirimat" PubChem, <https://pubchem.ncbi.nlm.nih.gov/compound/Tecovirimat>. Accessed 2 October, 2024.